Isoflavones:Acute Response in Chronic Renal Failure
异黄酮:慢性肾衰竭的急性反应
基本信息
- 批准号:6512078
- 负责人:
- 金额:$ 14.48万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2001
- 资助国家:美国
- 起止时间:2001-07-15 至 2003-12-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Up to 40 percent of ESRD patients suffer from a chronic inflammatory process which is not currently amenable to specific
treatment and is associated with high morbidity and mortality. High circulating
levels and production of pro-inflammatory cytokines are essential part of this
ongoing acute-phase response and they are believed to exacerbate many of the clinical manifestations of ESRD, including renal osteodystrophy. Like in all
other inflammatory processes that have undergone more extensive investigation,
the nuclear factor, Nuclear Factor Kappa-B (NFKB) promises to be a critical
cellular intermediate of this acute-phase response and to be both mediator and
target of inflammatory cytokine effects. In the current search for agents that
may be able to negate the ongoing acute-phase response of ESRD, the soy
isoflavones genistein and daidzein have emerged as potentially useful. These
isoflavones are present in many soyfoods, are available as over-the-counter
nutritional supplements and have received growing attention due to their
biological properties and potential as therapeutic agents. Inhibitory effects
of the isoflavones on tyrosine kinase and NFKB activity, on inflammatory
cytokine production and on oxidative stress have been demonstrated by this
group and by many other investigators and they may be highly relevant to the
renal failure population. Additionally, we have found recently that intake of
soy food by ESRD patients results in very high blood levels of isoflavones and
it is well tolerated.
It is our working hypothesis that in chronic renal failure a variety of
endogenous and exogenous factors trigger acute-phase response with activation
of NFKB and production of pro-inflammatory cytokines, and that intervention
with soy isoflavones inhibits NFKB activation and cytokines production, thus
blocking the ongoing acute-phase response and affecting positively clinically
relevant parameters of disease activity in ESRD.
Specific objective of this proposal is to conduct a randomized, double-blinded
dietary intervention trial in hemodialysis patients to determine whether:
1. Dietary intake of the soy isoflavones by ESRD patients with clinical signs
of ongoing acute-phase response decreases the production of the proinflammatory
cytokines TNF-alpha, IL-1 and IL-6 in peripheral blood, thus changing the
balance between these cytokines and their antagonists sTNF RI, sTNF RII, and
IL-1ra.
2. Suppression of inflammatory cytokine production by soy isoflavones is
associated with improvement of clinically relevant parameters of disease
activity, including improvement of blood markers of acute-phase response, and
decreased blood levels of markers of metabolic bone disease.
3. Intake of soy isoflavones suppresses NF-KB activity in peripheral blood
monocytic cells of ESRD patients, in a manner consistent with change of
cytokine levels and of clinical parameters of disease.
描述(由申请人提供):高达40%的终末期肾病患者患有慢性炎症过程,目前不符合特定的
而且与高发病率和高死亡率有关。高循环
促炎细胞因子的水平和产生是这一过程的重要组成部分
持续的急性期反应,据信会加重终末期肾病的许多临床表现,包括肾性骨营养不良。就像所有人一样
其他经过更广泛调查的炎症过程,
核因子,核因子Kappa-B(NFKB)有望成为关键
这一急性时相反应的细胞中间体,既是介体,又是
炎性细胞因子作用的靶点。在当前搜索的代理中,
可能能够否定ESRD正在进行的急性期反应,大豆
异黄酮染料木素和大豆苷元已成为潜在的有用成分。这些
异黄酮类存在于许多豆类食品中,可作为非处方药购买。
营养补充剂,并因其
生物学特性和作为治疗剂的潜力。抑制效应
异黄酮类化合物对酪氨酸激酶和NFKB活性的影响
细胞因子的产生和对氧化应激的影响已经被证明
小组和许多其他调查人员,他们可能与
肾功能衰竭人群。此外,我们最近发现,摄入的
ESRD患者的大豆食物会导致血液中非常高的异黄酮和
这是可以容忍的。
我们的工作假设是,在慢性肾功能衰竭中,各种
内源性和外源性因素通过激活触发急性期反应
NFKB和促炎细胞因子的产生,以及干预
大豆异黄酮可抑制NFKB的激活和细胞因子的产生,从而
阻断正在进行的急性期反应并对临床产生积极影响
ESRD疾病活动性的相关参数。
这项建议的具体目标是进行随机、双盲
对血液透析患者进行饮食干预试验,以确定:
1.有临床症状的终末期肾病患者膳食中大豆异黄酮类的摄入量
正在进行的急性时相反应减少了促炎因子的产生
外周血中的细胞因子TNF-α、IL-1和IL-6,从而改变
这些细胞因子与它们的拮抗剂sTNFRI、sTNFRII和
IL-1ra。
2.大豆异黄酮抑制炎性细胞因子的产生
与改善临床相关疾病参数有关
活动,包括改善急性期反应的血液标记物,以及
降低血液中代谢性骨病标志物的水平。
3.摄入大豆异黄酮会抑制外周血中核因子-KB的活性
终末期肾病患者外周血单核细胞的变化
细胞因子水平和疾病的临床参数。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PAOLO FANTI其他文献
PAOLO FANTI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PAOLO FANTI', 18)}}的其他基金
Correction of glutathione deficiency for treatment of diabetic nephropathy
纠正谷胱甘肽缺乏症治疗糖尿病肾病
- 批准号:
8392956 - 财政年份:2011
- 资助金额:
$ 14.48万 - 项目类别:
Correction of glutathione deficiency for treatment of diabetic nephropathy
纠正谷胱甘肽缺乏症治疗糖尿病肾病
- 批准号:
8250827 - 财政年份:2011
- 资助金额:
$ 14.48万 - 项目类别:
Correction of glutathione deficiency for treatment of diabetic nephropathy
纠正谷胱甘肽缺乏症治疗糖尿病肾病
- 批准号:
8586863 - 财政年份:2011
- 资助金额:
$ 14.48万 - 项目类别:
Correction of glutathione deficiency for treatment of diabetic nephropathy
纠正谷胱甘肽缺乏症治疗糖尿病肾病
- 批准号:
8045013 - 财政年份:2011
- 资助金额:
$ 14.48万 - 项目类别:
N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy
N-乙酰半胱氨酸和水飞蓟治疗糖尿病肾病
- 批准号:
8139104 - 财政年份:2009
- 资助金额:
$ 14.48万 - 项目类别:
N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy
N-乙酰半胱氨酸和水飞蓟治疗糖尿病肾病
- 批准号:
7590164 - 财政年份:2009
- 资助金额:
$ 14.48万 - 项目类别:
N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy
N-乙酰半胱氨酸和水飞蓟治疗糖尿病肾病
- 批准号:
7907541 - 财政年份:2009
- 资助金额:
$ 14.48万 - 项目类别:
PK OF SILYBIN-PHOSPHATIDYLCHOLINE COMPLEX (SILIPHOS) IN DIABETIC NEPHROPATHY
水飞蓟宾-磷脂酰胆碱复合物 (SILIPHOS) 在糖尿病肾病中的 PK
- 批准号:
7627561 - 财政年份:2007
- 资助金额:
$ 14.48万 - 项目类别:
PK OF SILYBIN-PHOSPHATIDYLCHOLINE COMPLEX (SILIPHOS) IN DIABETIC NEPHROPATHY
水飞蓟宾-磷脂酰胆碱复合物 (SILIPHOS) 在糖尿病肾病中的 PK
- 批准号:
7378222 - 财政年份:2006
- 资助金额:
$ 14.48万 - 项目类别:
Isoflavones:Acute Response in Chronic Renal Failure
异黄酮:慢性肾衰竭的急性反应
- 批准号:
6382644 - 财政年份:2001
- 资助金额:
$ 14.48万 - 项目类别:
相似海外基金
Decline of tissue stem cell proliferation and differentiation ability by chronic renal failure and preventive effects by omega-3 polyunsaturated fatty acid
慢性肾功能衰竭引起的组织干细胞增殖和分化能力下降及omega-3多不饱和脂肪酸的预防作用
- 批准号:
22K05529 - 财政年份:2022
- 资助金额:
$ 14.48万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Mechanism of hyperhomocysteinemia in chronic renal failure and its involvement in the development of cardiovascular disease
高同型半胱氨酸血症导致慢性肾功能衰竭的机制及其与心血管疾病发生发展的关系
- 批准号:
20K07188 - 财政年份:2020
- 资助金额:
$ 14.48万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Renal function and chronic renal failure mechanisms based on biomechanical modeling
基于生物力学模型的肾功能和慢性肾衰竭机制
- 批准号:
20K04281 - 财政年份:2020
- 资助金额:
$ 14.48万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Mechanisms of decline of cognitive functions by chronic renal failure involving neurogenesis
慢性肾衰竭涉及神经发生的认知功能下降机制
- 批准号:
17K01865 - 财政年份:2017
- 资助金额:
$ 14.48万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Analysis of intestinal microbiota and barrier function in chronic renal failure and therapeutic strategy
慢性肾功能衰竭肠道菌群及屏障功能分析及治疗策略
- 批准号:
17K09722 - 财政年份:2017
- 资助金额:
$ 14.48万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Clinical administration of AIM and establishment of renal function markers in cats with spontaneous chronic renal failure
自发性慢性肾功能衰竭猫的 AIM 临床应用及肾功能标志物的建立
- 批准号:
17K08097 - 财政年份:2017
- 资助金额:
$ 14.48万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Studies on the pathological mechanisms of feline morbillivirus associated with chronic renal failure
猫麻疹病毒与慢性肾功能衰竭相关病理机制的研究
- 批准号:
16K15039 - 财政年份:2016
- 资助金额:
$ 14.48万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
The role of Ca channels and KV1.3 channels in chronic renal failure and the development of preventive therapy against septic acute renal failure progressing to chronic hemodialysis
Ca通道和KV1.3通道在慢性肾功能衰竭中的作用以及脓毒症急性肾功能衰竭进展为慢性血液透析的预防治疗的发展
- 批准号:
16K20079 - 财政年份:2016
- 资助金额:
$ 14.48万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Molecular mechanism elucidation of iron metabolism abnormality and sarcopenia onset in chronic renal failure
慢性肾功能衰竭铁代谢异常和肌少症发病的分子机制阐明
- 批准号:
16K16603 - 财政年份:2016
- 资助金额:
$ 14.48万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Establishment of a new treatment strategy targeting inflammation for patients with chronic renal failure
建立针对慢性肾功能衰竭患者炎症的新治疗策略
- 批准号:
15K09289 - 财政年份:2015
- 资助金额:
$ 14.48万 - 项目类别:
Grant-in-Aid for Scientific Research (C)